Who is sponsoring NCT00212095?

NCT00212095 is sponsored by National University Hospital, Singapore.

What condition does NCT00212095 study?

NCT00212095 studies Metastatic Breast Cancer.

What drugs are being tested in NCT00212095?

Interventions: docetaxel and ketoconazole.

What is the status of NCT00212095?

NCT00212095 is currently COMPLETED.

Last reviewed 2012-10-31 · How we verify

Phase II Study of Docetaxel Combined With Ketoconazole in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor

NCT00212095 Phase 2 COMPLETED

Patients with locally advanced or metastatic breast cancer and with measurable primary breast tumor will be treated with 70mg docetaxel combined with ketoconazole. Serial tumor biopsies and plasma samples will be taken for gene expression and proteomics studies to identify biomarkers that may predict for treatment response.

Details

Lead sponsor	National University Hospital, Singapore
Phase	Phase 2
Status	COMPLETED
Enrolment	30
Start date	2005-06
Completion	2012-06

Conditions

Metastatic Breast Cancer

Interventions

docetaxel and ketoconazole

Primary outcomes

1. Evaluate the clinical response rate of 70mg docetaxel with ketoconazole in metastatic breast cancer. — 4 months
2. Evaluate the pathological response rate in the primary tumor following four cycles of docetaxel and ketoconazole. — 5 months

Countries

Singapore